Visiting Nurse & Hospice Care rebranding as VNA Health
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Iftiniuk: Understanding the power of ‘carism’
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Visiting Nurse & Hospice Care changing name to VNA Health
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sienna Biopharmaceuticals filing for Chapter 11 bankruptcy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Well Health creates communication system for patients, providers
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen trades cash for cash flow with Otezla deal
Amgen’s $13.4 billion acquisition of lucrative psoriasis therapy Otezla secures nearly a decade of revenue growth for the biotech giant to bridge the gap between its waning legacy products and potential new contenders. The relatively small deal could nonetheless change the landscape of the biotech industry, allowing regulators to approve a $74 billion takeover bid Read More →
Dubroff: 5 reasons to pay attention to Amgen’s Otezla deal
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
